InspireMD Inc. · NASDAQ:NSPR
InspireMD — Investor Presentation (October 2016)
25 slides from InspireMD's investor presentation, October 2016
Slide 1: Corporate Presentation
Corporate Presentation NYSE MKT: NSPR, NSPR.WS October 2016
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-lookin
Slide 3: Investment Highlights
Investment Highlights • Revenue growth driven by broader EU and Latin American launch of CGuard™ • Strategic distribution partnership with Penumbra (NYSE: PEN) • Multiple and consistent clinical trial results using CGuard in a broad patient population, including high risk patients • Expanding opport
Slide 4: Embolization Can Lead to Catastrophic Health Events
Embolization Can Lead to Catastrophic Health Events 4
Slide 5: Embolization Following Carotid Artery Stenting
Embolization Following Carotid Artery Stenting “Plaque protrusion through stent struts occurs in up to 65% of conventional carotid stents in relation to plaque morphology/symptomatic status and stent type, providing a mechanism for post carotid artery stenting (CAS) cerebral embolization, either dir
Slide 6: Consequences Range from Neurological Deficit to Stroke
Consequences Range from Neurological Deficit to Stroke Pre-Procedure Post-Procedure Pre-intervention showing 90% occlusion of the Post-intervention showing successful opening carotid artery and an MRI showing an old white of the occluded carotid artery with conventional matter infarction (obstructio
Slide 7: MicroNet Prevents Distal Embolization and Other Vascular Disease Challenges
MicroNet Prevents Distal Embolization and Other Vascular Disease Challenges • Proprietary technology • Ultrathin PET* mesh provides meaningful clinical benefit versus conventional devices • Provides revascularization benefit • MicroNet acts as “safety net” by offering greater vessel area coverage to
Slide 8: Large Addressable Market
Large Addressable Market Embolic Prevention Market Focus CE Mark Products Opportunity Area Coronary AMI & MGuard™* $1.7B SVG CGuard™ $500M Carotid (FDA IDE draft protocol synopsis) 2017E NGuard™ $675M Planned Neurovascular Submission 2018E PVGuard™ $1.7B Planned Peripheral Submission * MGuard is a b
Slide 9: Carotid Solution: Mesh Covered Technology
Carotid Solution: Mesh Covered Technology CGuard Embolic Prevention System(EPS) Combines stent and embolic protection in a single system • CE marked • Self-expanding nitinol stent • Emerging global market opportunity valued at $500M* • Positive CARENET data released 9/14, 1/15 and 5/16 documenting t
Slide 10: Positive CGuard Clinical Experience
Positive CGuard Clinical Experience CARENET Clinical Trial: 30 patient safety and efficacy clinical trial • Zero major adverse cardiac or cerebral events (MACCE) at 30 days (Comparative data 5.72%*) • 50% fewer new ischemic lesions with lesion volume being 10x times smaller compared to historical no
Slide 11: Additional Independent Clinical Data Supports Use of CGuard
Additional Independent Clinical Data Supports Use of CGuard* Independent study conducted in 30 patients with internal carotid artery disease Clinical results • 100% success in implanting the CGuard EPS • No peri- or post-procedural complications • No deaths, major adverse events, minor or major stro
Slide 12: Data Presented at CIRSE 2016
Data Presented at CIRSE 2016 Laboratory engineering evaluations • CGuard EPS provides high radial force and strong support in long stenotic lesions • Structure adapted well to changes in vessel diameter and direction • MicroNet mesh of CGuard EPS did not cause any measurable changes to specific mech
Slide 13: CGuard is a "Game Changing" Carotid Market Opportunity
CGuard is a “Game Changing” Carotid Market Opportunity Current standard of care: Carotid Endarterectomy (CEA) = Surgery The risk of post-procedural cerebral events has been related to [conventional] carotid stents* • Higher risks of stroke at 10 years appear to be attributable to the peri-procedural
Slide 14: Broad EU Commercialization Support from a Growing Neurovascular Leader
Broad EU Commercialization Support from a Growing Neurovascular Leader • Strategic distribution agreement with Penumbra • 18 European markets with opportunity to expand • Comprehensive neurovascular product portfolio • CGuard is a synergistic product offering • Growing direct sales force throughout
Slide 15: CGuard Country Case Study - Italy
CGuard Country Case Study - Italy 194% sales growth in Q2 2016, compared to Q2 2015 20% growth compared to the Q1 2016 Italy CGuard Revenue (in 000’s) $165 $137 $91 $56 $55 $28 Q1 15 Q2 Q3 Q4 Q1 16 Q2 * Setacci, et. al., J Cardiovasc Surg. 2015 May 21 15
Slide 16: Expanding Pipeline Opportunities with MicroNet
Expanding Pipeline Opportunities with MicroNet Commercial • CE Mark Cleared • 12-month MASTER I, II MGuard™ Coronary EPS Commercial • CE Mark Cleared Exploring Market • CARENET Trial Opportunity RGuard™ CGuard™ • PARADIGM all-comer trials Renal* Carotid • Wissgott 2016 data • FDA IDE draft protocol
Slide 17: Flow Diversion for Neurovascular Aneurysms
Flow Diversion for Neurovascular Aneurysms Objective • Seal the aneurysm and prevent rupture Current device therapies • Coils to pack the aneurysm • Flow diverters • Highly flexible, dense metal “tube” • Placed in main artery to seal off aneurysm and cause aneurysm thrombosis • Precise delivery requ
Slide 18: Innovation Enables Growth in the Neurovascular Market
Innovation Enables Growth in the Neurovascular Market Flow Diversion for Unruptured Brain Aneurysms Next Generation Technology • Aneurysm Therapy (all types): $550M* • Flow diverters are estimated to be 25% of the aneurysm market • Neurovascular products: estimated 15% CAGR from 2010-2016 2014 Compe
Slide 19: InspireMD Flow Diverter Advantage
InspireMD Flow Diverter Advantage • Low profile, flexible, open cell scaffold = Easy to deliver • Low metal ratio = Potential for reduced anti-thrombosis medication • Re-accessible through MicroNet = Allows for further treatment, if needed which is impossible with current flow diverters • Can be pla
Slide 20: Intellectual Property Portfolio
Intellectual Property Portfolio • Proprietary platform technology supported by a robust intellectual property portfolio. • Continue to strengthen and broaden patent protection globally. • Progress over the last year imparts important rights on existing products and technologies and will enable futur
Slide 21: Upcoming Anticipated Milestones
Upcoming Anticipated Milestones 2018E development towards PVGuard CE Mark Planned Submission CGuard approval and launch in India: H2 2017 CGuard: 2017 U.S. IDE submission NGuard Flow Diverter: 2017 CE Mark submission CGuard approval and launch in Russia: H1 2017 CGuard approval and launch in Brazil:
Slide 22: Leadership
Leadership Significant track records of success Dr. James Barry President and CEO Craig Shore CFO David Blossom VP Global Marketing & Strategy Dr. Sol Barer Chairman Isaac Blech Vice Chairman Michael Berman Director Paul Stuka Director Dr. Campbell Rogers Director Thomas Kester Director 22
Slide 23: Financial Snapshot
Financial Snapshot NYSE MKT: NSPR, NSPR.WS Stock Price (10/14/16): $2.65 Average Volume: 190 K Shares Outstanding (9/30/16): 1.4 M Shares Outstanding Including Future Pref. 3.6 M Stock Conv. (9/30/16): Market Capitalization (10/14/16): $9.6 M $0.9 M as of 6/30/2016 Total Cash: ($13M net proceeds fro
Slide 24: Investment Highlights
Investment Highlights • Revenue growth driven by broader EU and Latin American launch of CGuard • Strategic distribution partnership with Penumbra (NYSE: PEN) • Strong, and growing, direct sales teams across key countries • Significant growth in Italy over the last 4 quarters • Multiple and consiste
Slide 25: James Barry, Ph.D., President and CEO; Craig Shore, CFO
James Barry, Ph.D., President and CEO Craig Shore, CFO 888.776.6804 888.776.6804 jimb@inspiremd.com craigs@inspiremd.com